Michalak, Agata Laskowska, Katarzyna Radwan, Piotr Kasztelan-Szczerbinska, Beata Cybulski, Marek Cichoz-Lach, Halina
Published in
Current Issues in Pharmacy and Medical Sciences
Various laboratory parameters are commonly used to assess the efficacy of biological treatment (BT). The aim of our study was to assess the correlation between platelet (PLT) indices: (mean platelet volume (MPV), plateletcrit (PCT), platelet distribution width (PDW)), C-reactive protein (CRP) and endoscopic picture in the course of infliximab induc...
Bauer, Christina M Younis, Adam Herfarth, Hans Barnes, Edward L
Published in
Inflammatory bowel diseases
Gemayel, Nathalie C Rizzello, Eugenio Atanasov, Petar Wirth, Daniel Borsi, Andras
Published in
Current medical research and opinion
Background: Biologics used to treat ulcerative colitis (UC) may lose their effect over time, requiring patients to undergo dose escalation or treatment switching, and systematic literature reviews of real-world evidence on these topics are lacking. Aim: To summarize the occurrence and outcomes of dose escalation and treatment switching in UC patien...
Trivedi, Amruta Katelaris, Constance
Published in
Internal medicine journal
The uveitides are a heterogenous group of ocular inflammatory disorders that account for the third highest cause of blindness worldwide, responsible for 5-10% of visual impairment globally. Up to 35% of patients with uveitis can suffer significant vision loss. To prevent irreversible structural damage and blindness, it is important that the diagnos...
Matsuno, Hiroaki Matsubara, Tsukasa
Published in
Modern rheumatology
Objectives: This study aimed to demonstrate the equivalence of NI-071, an infliximab biosimilar (BS), and the infliximab reference product (RP) for treating Japanese patients with active rheumatoid arthritis (RA) refractory to methotrexate.Methods: In this multicenter two-period phase III study, patients were treated with BS or RP for 30 weeks (Per...
Sedano, Rocío Quera, Rodrigo Simian, Daniela Yarur, Andres J
Published in
Expert review of gastroenterology & hepatology
Introduction: Despite the introduction of novel therapies and treatment strategies for ulcerative colitis (UC), many patients develop acute, severe episodes, warranting prompt care and aggressive management. There is a significant unmet need to improve outcomes in these patients. Clinicians must be able to identify those that will have worse progno...
Campanati, Anna Paolinelli, Matteo Diotallevi, Frederico Martina, Emanuela Molinelli, Elisa Offidani, Annamaria
Published in
Expert opinion on drug metabolism & toxicology
Introduction: The treatment of psoriasis with conventional topical therapies and disease-modifying anti-rheumatic drugs (DMARDs) is often linked to unsatisfactory outcomes and the risk of serious adverse events. Over the last decades, research advances in understanding the role of tumor necrosis factor alpha (TNF α) and other cytokines in the patho...
Tanaka, Yoshiya Oba, Koji Koike, Takao Miyasaka, Nobuyuki Mimori, Tsuneyo Takeuchi, Tsutomu Hirata, Shintaro Tanaka, Eiichi Yasuoka, Hidekata Kaneko, Yuko
...
Published in
Annals of the rheumatic diseases
The aim of this study is to determine whether the 'programmed' infliximab (IFX) treatment strategy (for which the dose of IFX was adjusted based on the baseline serum tumour necrosis factor α (TNF-α)) is beneficial to induction of clinical remission after 54 weeks and sustained discontinuation of IFX for 1 year. In this multicentre randomised trial...
Chow, Vincent Oh, MyungShin Gessner, Melissa A Fanjiang, Gary
Published in
Clinical pharmacology in drug development
This was a randomized, single-blind, single-dose, 3-arm parallel-group study. Healthy subjects were randomized to receive ABP 710 (n = 50) or infliximab reference product (RP) sourced from the United States (infliximab US; n = 50) or the European Union (infliximab EU; n = 50) 5 mg/kg intravenously over 2 hours. The primary endpoint was area under t...
Aykan, Duygun Altintas Seyithanoglu, Muhammed
Published in
The Eurasian Journal of Medicine
Objective Statins inhibit the 3-hydroxy-3-methyl-glutaryl-CoA (HMG-CoA) reductase enzyme and thus reduce plasma cholesterol levels. Although decreased cholesterol level is the main target of anti-lipidemic drugs, cholesterol has an important role in the synthesis of lipid-based hormones such as testosterone. In this study, the alterations in serum ...
